BMS-Celgene Press Releases
Delivered December 17, 2019. Contributor: ChristineD
Goals
Obtain press releases that are related to the BMS/Celgene merger on a broader scale.
Early Findings
BMS-Celgene Press Releases
Bristol-Myers and Celgene's Liso-Cel
BMS Investors' Bet
OTEZLA Divestiture
- BMS has made it known that Celgene has reached a deal with Amgen.
- Under the deal, the global license for OTEZLA® (apremilast) will be bought by Amgen for $13.4 billion.
- This is linked to the acquisition of Celgene by BMS.
- BMS has stated in the past that it has decided to sell off OTEZLA as part of an ongoing regulatory approval procedure.
Proposed next steps:
You need to be the project owner to select a next step.